UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000032844
Receipt number R000037458
Scientific Title Efficacy of Evolocumab in patients with arteriosclerosis obliterans.
Date of disclosure of the study information 2018/06/02
Last modified on 2018/06/02 11:07:59

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Efficacy of Evolocumab in patients with arteriosclerosis obliterans.

Acronym

Efficacy of Evolocumab in patients with arteriosclerosis obliterans.

Scientific Title

Efficacy of Evolocumab in patients with arteriosclerosis obliterans.

Scientific Title:Acronym

Efficacy of Evolocumab in patients with arteriosclerosis obliterans.

Region

Japan


Condition

Condition

arteriosclerosis obliterans

Classification by specialty

Cardiology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To explore the efficay of evolocumab in patients with arteriosclerosis obliterans.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

the ratio of lower limb amputation after 48 weels

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Historical

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

evolocumab140mg/2weeks for 48 weeks

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Patients with arteriosclerosis obliterans
having
-Dyslipidemia undergoing treatment with HMG-CoA reductase inhibition
-LDL-C 100 mg/dL or more in conventional therapy

Key exclusion criteria

-HMG-CoA reductase inhibitor is not used at the time of introduction
-At the time of introduction of research drugs, patients with LDL-C less than 100 mg / dL
-Contraindicated patients with HMG-CoA reductase inhibitors
-Hypersensitivity to the study drug

Target sample size

20


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Hiroyasu Uzui

Organization

Faculty of Medical Sciences, University of Fukui

Division name

Department of Cardiovascular Medicine

Zip code


Address

23-3 Matsuokashimoaizuki, Eiheiji-cho, Yoshida-gun, Fukui

TEL

0776-61-8800

Email

huzui@u-fukui.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Hiroyasu Uzui

Organization

Faculty of Medical Sciences, University of Fukui

Division name

Department of Cardiovascular Medicine

Zip code


Address

23-3 Matsuokashimoaizuki, Eiheiji-cho, Yoshida-gun, Fukui

TEL

0776-61-8800

Homepage URL


Email

huzui@u-fukui.ac.jp


Sponsor or person

Institute

Department of Cardiovascular Medicine, Faculty of Medical Sciences, University of Fukui

Institute

Department

Personal name



Funding Source

Organization

none

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2018 Year 06 Month 02 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2018 Year 01 Month 25 Day

Date of IRB


Anticipated trial start date

2018 Year 02 Month 01 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2018 Year 06 Month 02 Day

Last modified on

2018 Year 06 Month 02 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000037458


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name